| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -50,130 | -44,918 |
| Depreciation and amortization | 15,488 | 10,315 |
| Stock-based compensation | 67,177 | 46,171 |
| Amortization of premium and accretion of discounts, net | 2,165 | 1,273 |
| Amortization of operating lease right-of-use assets | 4,264 | 2,816 |
| Amortization of debt discount | 2,310 | 1,564 |
| Change in fair value of strategic investments | 3,889 | 2,995 |
| Provision for credit losses and contractual allowances | 80,161 | 54,704 |
| Acquired in-process research and development | 2,296 | 1,994 |
| Loss on extinguishment of debt | 0 | 0 |
| Impairment charges | 2,479 | 2,479 |
| Other | 962 | 172 |
| Accounts receivable | 76,377 | 56,916 |
| Inventory | 6,450 | 4,601 |
| Prepaid expenses and other current assets | 2,817 | 1,541 |
| Other assets | 3,425 | -283 |
| Accounts payable and accrued liabilities | 29,689 | 14,682 |
| Deferred revenue | 1,292 | 567 |
| Operating lease liabilities | -6,214 | -3,735 |
| Net cash provided by (used in) operating activities | 54,651 | 19,768 |
| Purchases of property and equipment | 34,619 | 19,788 |
| Purchases of marketable securities | 340,539 | 169,466 |
| Maturities of marketable securities | 149,200 | 50,200 |
| Purchases of strategic investments | 2,300 | 0 |
| Purchases of acquired in-process research and development | 0 | - |
| Net cash used in investing activities | -228,258 | -139,054 |
| Payments of debt-Silicon Valley Bank Term Loan | 0 | 0 |
| Proceeds from braidwell debt-Braidwell Term Loan Facility | 0 | 0 |
| Payments of issuance costs-Braidwell Term Loan Facility | 0 | 0 |
| Payments of debt-Braidwell Term Loan Facility | 0 | 0 |
| Proceeds from issuance of 2029 notes-Convertible Notes Due2029 | 0 | 0 |
| Payments of issuance costs-Convertible Notes Due2029 | 0 | 0 |
| Purchases of capped call transactions | 0 | 0 |
| Purchase of treasury stock | 0 | 0 |
| Proceeds from issuance of common stock in connection with employee equity incentive plans | 9,648 | 8,823 |
| Net cash provided by financing activities | 9,648 | 8,823 |
| Effect of exchange rate changes | -33 | -29 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -163,992 | -110,492 |
| Cash and cash equivalents at beginning of period | 427,955 | - |
| Cash and cash equivalents at end of period | 263,963 | - |
iRhythm Technologies, Inc. (IRTC)
iRhythm Technologies, Inc. (IRTC)